Technology
Health
Medical

PAVmed

$1.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.97%) Today
-$0.02 (-1.92%) After Hours

Why Robinhood?

You can buy or sell PAVmed and other stocks, options, ETFs, and crypto commission-free!

About

PAVmed Inc. Common Stock, also called PAVmed, is a medical device company, which develops and commercializes a pipeline of medical products. Read More Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Employees
5
Headquarters
New York, New York
Founded
2014
Market Cap
27.34M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
365.08K
High Today
$1.04
Low Today
$1.03
Open Price
$1.04
Volume
52.79K
52 Week High
$1.80
52 Week Low
$0.86

Collections

Technology
Health
Medical
2016 IPO
US
North America

News

Markets InsiderMar 21

PAVmed to Hold Business Update Conference Call on April 4, 2019

NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth quarter 2018 financial results on or before April 4, 2019 and host a conference call on Thursday, April 4, 2019 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the C...

89
Markets InsiderFeb 26

PAVmed Provides Business Update

NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its business. “I am pleased to report that PAVmed’s 2019 is off to an excellent start with continued progress as we approach multiple value-creating milestones,” said Lishan Aklog M.D., PAVmed’s Chairman and CEO. “With CarpX’s first-in-human (FIH) 510(k) clinical safety study in process, EsoCheck CCD’s 510(k) app...

318

Earnings

-$0.16
-$0.13
-$0.11
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 14, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.